Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2008-07-22
2008-07-22
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C530S351000
Reexamination Certificate
active
10673886
ABSTRACT:
Polynucleotides and polypeptides derived from the nucleotide sequence of the IFNα-21 gene comprising SNPs, and their therapeutic uses.
REFERENCES:
patent: 6299877 (2001-10-01), Chen et al.
patent: 6482613 (2002-11-01), Goeddel et al.
patent: 0 173 887 (1987-07-01), None
patent: 2 079 291 (1982-01-01), None
patent: WO 84/00776 (1984-03-01), None
patent: WO 00/39280 (2000-07-01), None
patent: WO 01/25438 (2001-04-01), None
Mickle JE, et al. Genotype-phenotype relationships in cystic fibrosis. Med. Clin. North Am. 2000. vol. 84, No. 3, pp. 597-607.
David V. Goeddel et al., “The structure of eight distinct cloned human leukocyte interferon cDNAs,” Nature vol. 290, Mar. 5, 1981, pp. 20-26.
Axel Ullrich et al., “Nucleotide Sequence of a Portion of Human Chromosome 9 Containing a Leukocyte Interferon Gene Cluster,” J. Mol. Biol. (1982) 156, pp. 467-486.
H. Weber et al., “Single amino acid changes that render human IFN-α2 biologically active on mouse cells,” The EMBO Journal, vol. 6, No. 3, pp. 591-598, 1987.
Ann-Christine Syvänen et al., “Identification of Individuals by Analysis of Biallelic DNA Markers, Ising PCR and Solid-Phase Minisequencing,” Am. J. Genet., vol. 52, pp. 46-59, 1993.
Musaddeq Hussain et al., “Identification of Interferon-α7, -α14, and -α21 Variants in the Genome of a Large Human Population,” Journal of Interferon And Cytokine Research, vol. 16, pp. 853-859, (1996).
Rob L. H. Jansen et al., “Interleukin-2 and Interferon-α in the Treatment of Patients with Advanced Non-Small-Cell Lung Cancer,” Journal Of Immunotherapy, vol. 12, No. 1, 1992, pp. 70-73.
Eiji Mita et al., “Predicting Interferon Therapy Efficacy from Hepatitis C Virus Genotype and RNA Titer,” Digestive Diseases and Science, vol. 39, No. 5, (May 1994), pp. 977-982.
Ryo Yamada et al., “Identification of 142 single nucleotide polymorphisms in 41 candidate genes for rheumatoid arthritis in the Japanese population,” Hum. Genet. (2000), vol. 106, pp. 293-297.
O. I. Olopade et al., “Mapping of the Shortest Region of Overlap of Deletions of the Short Arm of Chromosome 9 Associated with Human Neoplasia,” Genomics 14, pp. 437-443 (1992).
International Search Report dated Jun. 13, 2003 for Application No. PCT/EP02/04082.
Accession No. NM—002175 “Homo sapiensinterferon, alpha 21 (IFNA21), mRNA” (1998).
Accession No. AC009445 “Homo sapiensclone PR11-1P8” (Sep. 10, 2000).
Swiss-Prot entry P05007 “Interferon alpha-A [Precursor]” (Aug. 13, 1987).
Genodyssee, S.A.
Hissong Bruce D.
Hunton & Williams LLP
Landsman Robert
LandOfFree
Polypeptides of the IFNα-21 gene does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptides of the IFNα-21 gene, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptides of the IFNα-21 gene will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3940384